Researchers at the Herbert Wertheim UF Scripps Institute unveiled MT-125, a novel drug targeting non-muscle myosin IIA and IIB, that sensitizes glioblastoma tumors to radiation and kinase inhibitors in preclinical mouse models. By disrupting mitochondrial dynamics and triggering ferroptosis, MT-125 effectively inhibits tumor invasion and promotes long-term remission in a subset of treated animals. This approach offers a promising strategy to overcome resistance in one of the deadliest brain cancers, potentially enabling combination regimens with existing therapeutics.